Clinical

A recent study found that the Service Apothecary Respiratory Advice eHealth intervention could help patients with chronic obstructive pulmonary disease with exacerbation rates and medication adherence.

Prior miscarriage and antinuclear antibody positivity are independent risk factors associated with adverse pregnancy outcomes among women with rheumatoid arthritis (RA).

Drs Noble and Highland explain the typical treatment goals physicians aim for when looking at ILD therapy options.

Ryan Haumschild, PharmD, MS, MBA, and Kristin Highland, MD, explain the clinical and economic burdens associated with ILD treatment.

Two experts highlight their preferred treatment options for RRMM based on each line of therapy the patient will need.

Drs Kaufman and Richter outline important considerations physicians should be aware of when selecting IMiD therapy for a patient with RRMM.

The FDA is faster to approve new oncology therapies compared with the European Medicines Agency (EMA); but that speed may have consequences.

Arwen Podesta, MD, provides an overview of how PDTs have evolved over the past 6 years since their introduction into the medical world.

Two experts define prescription digital therapeutics (PDTs) and their role in behavioral care therapy.

Oxidative stress, including DNA damage and malondialdehyde, was associated with dementia in patients with chronic obstructive pulmonary disease (COPD).

While no agents are approved just yet, a variety of promising drugs targeting CLDN18.2 are undergoing early research and clinical trials for several cancer types. 

Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic syndromes (MDS) and the applicability of a novel scoring system, presented during her plenary session at EHA2022, that aims to improve and refine MDS risk estimation.

John Mascarenhas, MD, director of the Adult Leukemia Program at The Tisch Cancer Institute at Mount Sinai, spoke on preliminary data findings of the phase 2 MANIFEST study investigating the efficacy and safety profile of pelabresib, ruxolitinib combination therapy in JAK inhibitor-naive patients with myelofibrosis and those with suboptimal response to ruxolitinib monotherapy.

A primary analysis of the phase 2 ROSEWOOD trial finds that a combination of zanubrutinib and obinutuzumab is superior to obinutuzumab alone in relapsed/refractory follicular lymphoma (FL). Results were presented at the 2022 European Hematology Association Congress.

The late-breaking oral session at the 2022 European Hematology Association (EHA) Congress allowed investigators to present recently emerging data from abstracts submitted after the deadline, including outcomes from trials in chronic lymphocytic leukemia, multiple myeloma, and sickle cell disease.

The study suggests standardized uptake values may be a useful marker to predict treatment response and prognosis in lung adenocarcinoma.

Despite a greater risk of cardiovascular disease (CVD) due to exposure to chemotherapy and/or radiation, adult survivors of childhood cancer are undertreated for CVD risk factors compared with the general population.

During a session at the 2022 European Hematology Association Congress, speakers discussed how artificial intelligence (AI) can help advance the principles of ethical medicine—but also how new technologies are being used to undermine the integrity of scientific research.

The investigators cautioned, however, that the factors identified had only modest predictive power.

Abstracts presented at the 2022 European Hematology Association Congress demonstrate superior health-related quality of life (HRQOL) outcomes among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) taking zanubrutinib.

Physicians should consider measuring anti-endothelial cell antibodies in patients with polycythemia vera, the investigators suggested.

The long-term study also found persistent residual risk of heart failure even after smoking cessation

Using biosimilar rituximab to replace the reference in a common combination regimen to treat diffuse large B-cell lymphoma (DLBCL) results in similar outcomes.

Finding therapeutic targets for acute myeloid leukemia (AML) has proven challenging, but a set of immune-regulating molecules may hold promise as biomarkers and targets.

In abstracts featured at the 2022 European Hematology Association Congress, investigators detailed long-term results of the ASPEN phase 3 trial and an expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia (WM).

GlaxoSmithKline (GSK) aims to have its respiratory syncytial virus (RSV) vaccine reviewed later this year; Northwell Health and Kaiser Permanente among CEOs supporting gun legislation; Infants whose mothers had COVID-19 during their pregnancy had double the risk of delayed speech or motor skills.

A systematic review and meta-analysis found no clear advantage for automated red cell exchange.

An education session at the 2022 European Hematology Association Congress featured updates on using genetic and immune characteristics to select the optimal treatment pathway in chronic lymphocytic leukemia (CLL).

Abstracts presented at EULAR 2022 focused on sex-related differences in inflammatory arthritis (IA) management, including adherence to electronically reporting outcomes and disparities in health care utilization.

Study data are mixed, but some evidence suggests the administration of vitamin D may work as a low-risk prophylactic against graft-versus-host disease (GVHD).